当前位置: 首页 >> 检索结果
201. Morbidity After Takotsubo Syndrome: A Report From the Scottish Takotsubo Registry.
作者: Amelia E Rudd.;Graham W Horgan.;Jim McGowan.;Arvind Sood.;Ross McGeoch.;John Irving.;Jonathan Watt.;Stephen J Leslie.;Mark C Petrie.;Chim C Lang.;Nicholas L Mills.;David E Newby.;Dana K Dawson.
来源: Ann Intern Med. 2025年178卷5期754-757页 206. Patients' Values and Preferences Regarding the Pharmacologic Treatment of Acute Episodic Migraine : A Rapid Review.
作者: Kylie Thaler.;Camilla Neubauer-Bruckner.;Johanna Feyertag.;Arianna Gadinger.;Emma Persad.;Andrea Chapman.;Gernot Wagner.;Irma Klerings.;Gerald Gartlehner.
来源: Ann Intern Med. 2025年178卷4期525-532页
Understanding patients' values and preferences is essential for guideline development.
209. Pharmacologic Treatment of Acute Attacks of Episodic Migraine: A Systematic Review and Network Meta-analysis for the American College of Physicians.
作者: Gerald Gartlehner.;Andreea Dobrescu.;Gernot Wagner.;Andrea Chapman.;Emma Persad.;Claus Nowak.;Irma Klerings.;Camilla Neubauer.;Johanna Feyertag.;Arianna Gadinger.;Kylie Thaler.
来源: Ann Intern Med. 2025年178卷4期507-524页
Migraine is common, affecting 15% of Americans.
210. Acute Pain Management in People With Opioid Use Disorder : A Systematic Review.
作者: Michele J Buonora.;Katherine Mackey.;Laila Khalid.;Thomas R Hickey.;Alyssa A Grimshaw.;Max Moss.;Joanna L Starrels.;Daniel P Alford.;William C Becker.;Melissa B Weimer.
来源: Ann Intern Med. 2025年178卷4期558-570页
Guidance on acute pain management among people with opioid use disorder (OUD) is limited.
212. Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians.
作者: Amir Qaseem.;Jeffrey A Tice.;Itziar Etxeandia-Ikobaltzeta.;Timothy J Wilt.;Curtis S Harrod.;Thomas G Cooney.;Carolyn J Crandall.; .;Lauri A Hicks.;Ethan Balk.;J Thomas Cross.;Nick Fitterman.;Johanna Lewis.;Amy M Linsky.;Michael Maroto.;Matthew C Miller.;Adam J Obley.;Douglas K Owens.;Paul G Shekelle.;Tatyana Shamliyan.;Jennifer Yost.
来源: Ann Intern Med. 2025年178卷4期571-578页
The American College of Physicians (ACP) developed this guideline based on the best available evidence on the comparative benefits and harms of pharmacologic treatments of acute episodic migraine headache, patients' values and preferences, and economic evidence about these pharmacologic treatments.
217. Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda : A Cross-Sectional Study.
作者: Mark J Siedner.;Brian Ghoshhajra.;Geoffrey Erem.;Rita Nassanga.;Mangun Randhawa.;Andrew Ochieng.;Moses Acan.;Michael T Lu.;Vikas Thondapu.;Angelo Takigami.;Zahra Reynolds.;Flavia Atwiine.;Edna Tindimwebwa.;Rebecca F Gilbert.;Eliza Passell.;Shruti Sagar.;Yao Tong.;Ntobeko A B Ntusi.;Alexander C Tsai.;Prossy Bibangambah.;Thomas Gaziano.;Susanne S Hoeppner.;Christopher T Longenecker.;Samson Okello.;Stephen Asiimwe.
来源: Ann Intern Med. 2025年178卷4期468-478页
Data on the prevalence of coronary atherosclerotic disease (CAD) in the African region among people with and without HIV are lacking.
218. Health Care Delivery of Clinical Preventive Services for People With Disabilities : A Systematic Review.
作者: David I Buckley.;Frances Hsu.;Tracy Dana.;Keeley Blackie.;Rebecca Holmes.;Peggy Nygren.;Willi Horner-Johnson.;Christina Nicolaidis.;Roger Chou.
来源: Ann Intern Med. 2025年178卷5期671-686页
People with disabilities are less likely than the general population to receive clinical preventive services.
219. Gout.
Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting in painful recurrent flares and tissue damage. Gout is the most common form of inflammatory arthritis, with a prevalence of 5.1% in the United States, affecting 12.1 million adults. When urate levels exceed the limit of solubility (6.8 mg/dL [400 μmol/L]), MSU crystals may form or grow. Gout flares are the result of inflammatory responses to MSU crystals. The primary method to prevent and reduce gout flares, tophi, chronic inflammatory arthritis, and joint damage is to reduce urate levels below the saturation threshold. The pathophysiology of gout is well understood, and inexpensive and effective therapies are available. However, outcomes for patients with gout remain poorly optimized.
|